Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company dedicated to advancing patient care, announced today its participation in the upcoming 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 5th to 8th in Boston, MA. The company will showcase clinical data and insights on two of its cutting-edge technologies, the OMNI Surgical System and the TearCare System, through oral presentations and posters.
The OMNI Surgical System facilitates a comprehensive, implant-free, minimally invasive glaucoma surgical procedure for adults with primary open-angle glaucoma (POAG). On the other hand, the TearCare System offers an interventional eyelid procedure for diseased meibomian glands, addressing evaporative dry eye disease (DED) due to meibomian gland dysfunction.
“We are thrilled to present additional data supporting the effectiveness and safety of our OMNI and TearCare technologies at ASCRS, a premier event for anterior segment surgeons,” stated Paul Badawi, CEO and co-founder of Sight Sciences. “Our extended clinical evidence underscores the long-term benefits of the OMNI procedure and the significant improvements provided by TearCare for patients with dry eye disease.”
One of the highlights will be the presentation on the 36-month outcomes of the OMNI Surgical System, demonstrating sustained efficacy over an extended period. Additionally, TearCare-related presentations will focus on the improvement of tear break-up, meibomian gland function, and dry eye symptoms in treated patients.
Sight Sciences will also host a red carpet event at its booth (#545) during ASCRS, underscoring its commitment to enhancing eyecare. The event will take place on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
About Sight Sciences Sight Sciences is a pioneering eyecare technology company dedicated to revolutionizing patient care. Its OMNI Surgical System offers implant-free glaucoma surgery, while the TearCare System provides innovative solutions for evaporative dry eye disease. Through its innovative approaches, Sight Sciences aims to enhance patient care and replace outdated treatment methods.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. These statements involve risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed. Sight Sciences undertakes no obligation to update forward-looking statements, except as required by law.
